Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | GLA | P06280 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580654 | 0.84 | ALDH1A1 (0.66) | ALDH1A1TSHRGLATP53MEN1 | |
| SCHEMBL7778963 | 0.84 | TP53 (0.58) | ALDH1A1TSHRGLATP53MEN1 | |
| SCHEMBL11190753 | 0.83 | ALDH1A1 (0.70) | ALDH1A1TSHRGLATP53MEN1 | |
| SCHEMBL380050 | 0.83 | ALDH1A1 (0.76) | ALDH1A1TSHRGLATP53MEN1 | |
| SCHEMBL1185690 | 0.83 | ALDH1A1 (0.76) | ALDH1A1TSHRGLATP53MEN1 | |
| SCHEMBL263716 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TSHRGLATP53MEN1 | |
| SCHEMBL11738442 | 0.82 | CYP3A4 (0.60) | ALDH1A1TSHRGLATP53CYP3A4 | |
| SCHEMBL2816243 | 0.81 | NPC1 (0.62) | ALDH1A1TSHRGLATP53MEN1 | |
| SCHEMBL9679324 | 0.81 | ALDH1A1 (0.52) | ALDH1A1TSHRGLATP53MEN1 | |
| Hydrochloric Acid SCHEMBL3454478 | 0.81 | ALDH1A1 (0.73) | ALDH1A1TSHRGLATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3015467-B1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO KK (JP) | 2024-12-04 | — | — | EP | claimed |
| WO-1998017276-A1 | HETEROARYL SPIROETHERCYCLOALKYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | claimed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-4695265-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | Bachem Holding AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4678626-A1 | LONG-CHAIN ALKENYLOXY-SUBSTITUTED BENZOYL DERIVATIVE AND OLIGONUCLEOTIDE SYNTHESIS METHOD USING SAME | Spera Pharma, Inc. (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20260001902-A1 | IMPROVED OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-12509484-B2 | Method of producing nucleic acid compound, and nucleic acid compound | FUJIFILM CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| EP-4605403-B1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2025-11-26 | — | — | EP | disclosed |
| EP-4605403-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | Bachem Holding AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4590684-A1 | IMPROVED OLIGONUCLEOTIDE SYNTHESIS | Bachem Holding AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| EP-0241735-A2 | Acyloxythiophene carbon amide | BAYER AG (DE) | 1987-10-21 | — | — | EP | disclosed |
| US-4257804-A | HERBICIDE | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-03-24 | — | — | US | disclosed |
| US-4256881-A | Blocked benzotriazole compounds as development restrainer precursors | EASTMAN KODAK COMPANY (US) | 1981-03-17 | — | — | US | disclosed |
| US-4255510-A | DIFFUSION TRANSFER, AZOLES | EASTMAN KODAK COMPANY (US) | 1981-03-10 | — | — | US | disclosed |
| US-4053298-A | HERBICIDAL COMPOSITIONS CONTAINING 1-THIADIAZOLYL-6-CARBAMOYLOXYTETRAHYDROPYRIMIDINONES AND METHODS THEREFOR | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
| US-4046909-A | Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
| US-4023957-A | Herbicidal 1-thiadiazolyl-5-carbamoyloxyimidazolidinones | VELSICOL CHEMICAL CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3998958-A | Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-12-21 | — | — | US | disclosed |
| US-3951976-A | 1-Thiadiazoly-6-carbamoyloxytetrahydropyrimidinones | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | ALDH1A1 3477/4885TSHR 1378/4885GLA 1953/4885 |
| US-12509484-B2 | Method of producing nucleic acid compound, and nucleic acid compound | NSUN2, RNASEH1, XRN2 | ALDH1A1 2662/4885TSHR 941/4885GLA 3925/4885 |
| US-20260001902-A1 | IMPROVED OLIGONUCLEOTIDE SYNTHESIS | MED1, POLRMT, CPSF6 | ALDH1A1 1937/4885TSHR 1015/4885GLA 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.